PMV Pharmaceuticals, Inc. (PMVP) Income Statement
PMVP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPMVP revenue and net income
PMVP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PMVP quarterly EPS vs estimates
PMV Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.31).
PMVP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $133,000 | $1.1M | $1.3M | $650,000 | $1.3M | $318,000 | $388,000 | $338,000 |
| Gross profit | −$133,000 | −$1.1M | −$1.3M | −$650,000 | −$1.3M | −$318,000 | −$388,000 | −$338,000 |
| Research & development | $69.9M | $57.4M | $54.6M | $52.0M | $36.5M | $23.9M | $20.8M | $13.9M |
| Sales, general & admin | $16.3M | $26.9M | $24.2M | $25.1M | $21.8M | $11.0M | $5.9M | $5.0M |
| Total operating expenses | $86.2M | $84.3M | $78.9M | $77.0M | $58.3M | $34.9M | $26.2M | $18.9M |
| Operating income | −$86.2M | −$85.4M | −$80.1M | −$77.0M | −$58.3M | −$34.9M | −$26.6M | −$18.9M |
| Interest income | $6.3M | $10.7M | $9.8M | $3.6M | $449,000 | $651,000 | $1.3M | $1.3M |
| Interest expense | — | — | — | $4.0M | $777,000 | $826,000 | $1.3M | $0 |
| Income before taxes | −$79.9M | −$74.8M | −$69.0M | −$73.3M | −$57.8M | −$34.4M | −$25.3M | −$17.5M |
| Income taxes | −$2.2M | −$16.1M | $2,000 | −$9,000 | $23,000 | $6,000 | $8,000 | $3,000 |
| Net income | −$77.7M | −$58.7M | −$69.0M | −$73.3M | −$57.8M | −$34.4M | −$25.4M | −$17.5M |
| EBITDA | −$79.8M | −$73.7M | −$67.7M | −$76.7M | −$58.0M | −$34.6M | −$25.0M | −$18.6M |
| EPS (diluted) | −$1.49 | −$1.14 | −$1.45 | −$1.62 | −$1.28 | −$1.76 | −$0.81 | −$5.85 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.6M | $0 |
| Cost of revenue | — | $34,000 | $33,000 | $32,000 | $32,000 | — | — | — | $372,000 | $362,000 | $359,000 | $358,000 |
| Gross profit | — | −$34,000 | −$33,000 | −$32,000 | −$32,000 | — | — | — | −$372,000 | −$362,000 | −$359,000 | −$358,000 |
| Research & development | $14.7M | $15.3M | $15.8M | $18.2M | $18.4M | $17.4M | $13.8M | $16.9M | $14.3M | $12.8M | $13.0M | $13.6M |
| Sales, general & admin | $4.2M | $3.7M | $3.4M | $4.3M | $4.5M | $4.1M | $11.4M | $4.9M | $5.5M | $5.0M | $5.5M | $6.0M |
| Total operating expenses | $18.9M | $19.0M | $19.2M | $22.5M | $22.8M | $21.6M | $25.2M | $21.9M | $19.8M | $17.9M | $18.5M | $19.6M |
| Operating income | −$18.9M | −$19.0M | −$19.2M | −$22.5M | −$22.9M | −$21.6M | −$25.2M | −$21.9M | −$20.2M | −$18.2M | −$18.9M | −$19.6M |
| Interest income | $788,000 | $980,000 | $1.2M | $1.5M | $1.7M | $1.9M | $2.3M | $2.6M | $2.8M | $3.0M | $3.2M | $3.0M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.4M | — |
| Income before taxes | −$18.1M | −$18.0M | −$18.0M | −$21.1M | −$21.2M | −$19.6M | −$23.0M | −$19.2M | −$17.4M | −$15.3M | −$15.8M | −$16.6M |
| Income taxes | $3,000 | — | $26,000 | −$6,000 | $5,000 | −$2.2M | — | $74,000 | −$16.2M | $318,724 | −$1,000 | −$358,000 |
| Net income | −$18.1M | −$18.0M | −$18.0M | −$21.1M | −$21.2M | −$17.4M | −$23.0M | −$19.2M | −$1.2M | −$15.3M | −$15.8M | −$16.6M |
| EBITDA | −$18.9M | −$18.0M | −$18.0M | −$21.0M | −$21.2M | −$19.6M | −$23.0M | −$18.8M | −$17.0M | −$14.9M | −$15.4M | −$16.3M |
| EPS (diluted) | −$0.34 | −$0.34 | −$0.34 | −$0.40 | −$0.41 | −$0.34 | −$0.45 | −$0.37 | −$0.02 | −$0.30 | −$0.31 | −$0.34 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | −22.2% | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | −1,168.2% | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | −973.8% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PMVP's financial statements (latest annual report filed March 6, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PMVP financial results
PMV Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $77.7 million. Diluted earnings per share came to −$1.49.
See the PMVP stock overview for the latest quote and news, or the PMVP chart for price history and technical indicators.
PMVP income statement FAQ
Does PMV Pharmaceuticals have revenue?
PMV Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is PMV Pharmaceuticals profitable?
No. PMV Pharmaceuticals reported a net loss of $77.7 million in fiscal 2025.
How much does PMV Pharmaceuticals spend on research and development?
PMV Pharmaceuticals spent $69.9 million on research and development in fiscal 2025.
What are PMV Pharmaceuticals's earnings per share?
PMV Pharmaceuticals earned $-1.49 per diluted share in fiscal 2025, compared with $-1.14 a year earlier.
When will PMV Pharmaceuticals report its next earnings?
PMV Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does PMV Pharmaceuticals's fiscal year end?
PMV Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 6, 2026.